SOURCE Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated
Multiple Myeloma Patients www.marketwatch.com Dec. 7, 2008
January 3, 2009
December 2008 Data presented at the 50th Annual Meeting of the American Society of
Hematology (ASH), held December 5-9, 2008 in San Francisco, suggested the combination of four
drugs (VELCADE, dexamethasone, cyclophosphamide and lenalidomide (VcDCR)) was with
previously untreated multiple myeloma (MM).